Endothelial Function of von Hippel-Lindau Tumor Suppressor Gene: Control of Fibroblast Growth Factor Receptor Signaling
Authors:
Open Access
- 15 June 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (12) , 4649-4657
Abstract
Von Hippel-Lindau (VHL) disease results from germline and somatic mutations in the VHL tumor suppressor gene and is characterized by highly vascularized tumors. VHL mutations lead to stabilization of hypoxia-inducible factor (HIF), which up-regulates proangiogenic factors such as vascular endothelial growth factor (VEGF). This pathway is therefore believed to underlie the hypervascular phenotypes of the VHL tumors. However, recent studies have identified novel VHL functions that are independent of the HIF-VEGF pathway. In addition, a potential role of VHL in the tumor microenvironment, which carries heterozygous VHL mutations in VHL patients, has been overlooked. Here, we report a novel HIF-independent VHL function in the endothelium. VHL knockdown in primary human microvascular endothelial cells caused defective turnover of surface fibroblast growth factor (FGF) receptor, increased extracellular signal-regulated kinase signaling, and ETS1 activation, leading to increased cell motility in response to FGF and three-dimensional cord formation in vitro. HIF-α knockdown in VHL loss-of-function endothelial cells does not impede their elevated in vitro angiogenic activity. Importantly, the elevated angiogenic response to FGF is recapitulated in Vhl-heterozygous mice. Thus, partial loss of function of VHL in endothelium may be a contributing factor in tumor angiogenesis through a HIF-VEGF–independent mechanism. [Cancer Res 2008;68(12):4649–57]Keywords
All Related Versions
This publication has 50 references indexed in Scilit:
- Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL -mutant renal carcinoma cellsCarcinogenesis, 2008
- Drosophila dopamine synthesis pathway genes regulate tracheal morphogenesisDevelopmental Biology, 2007
- Anti‐angiogenic therapy in renal cell cancerBJU International, 2007
- Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapyNature Clinical Practice Oncology, 2006
- pVHL Function Is Essential for Endothelial Extracellular Matrix DepositionMolecular and Cellular Biology, 2006
- Isolation, culture, and characterization of endothelial cells from mouse glomeruliKidney International, 2004
- von Hippel-Lindau Tumor Suppressor Protein and Hypoxia-Inducible Factor in Kidney CancerAmerican Journal of Nephrology, 2004
- Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor GrowthPLOS Biology, 2003
- Signal transduction and the Ets family of transcription factorsOncogene, 2000
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993